Indian Pharmas To Fall Short Of Export Forecasts
This article was originally published in PharmAsia News
India's pharmaceutical business is expected to miss 2007-2008 export growth forecasts by 23 percent. The industry blames the appreciation of the rupee for the projected failure to reach the 30 percent growth forecast. Also cited for the fall-off were pricing pressures and loss of patent protection in the United States. Others cite a U.S. recession that forces foreign companies to offer greater discounts. (Click here for more
You may also be interested in...
AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.